Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma

Aim Transarterial chemoembolization (TACE) combined with a PD‐1 inhibitor and TACE combined with a PD‐1 inhibitor and lenvatinib have recently been reported as promising treatments to improve the prognosis of hepatocellular carcinoma (HCC) patients. This study aims to compare the efficacy of these t...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2022-08, Vol.52 (8), p.721-729
Main Authors: Xiang, Yan‐Jun, Wang, Kang, Yu, Hong‐Ming, Li, Xiao‐Wei, Cheng, Yu‐Qiang, Wang, Wei‐Jun, Feng, Jin‐Kai, Bo, Meng‐Han, Qin, Ying‐Yi, Zheng, Yi‐Tao, Shan, Yun‐Feng, Zhou, Li‐Ping, Zhai, Jian, Cheng, Shu‐Qun
Format: Article
Language:English
Subjects:
Disease control
Hepatocellular carcinoma
lenvatinib
Liver cancer
Medical prognosis
Patients
sintilimab
Solid tumors
toripalimab
transarterial chemoembolization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Transarterial chemoembolization (TACE) combined with a PD‐1 inhibitor and TACE combined with a PD‐1 inhibitor and lenvatinib have recently been reported as promising treatments to improve the prognosis of hepatocellular carcinoma (HCC) patients. This study aims to compare the efficacy of these two treatments. Methods A retrospective study was conducted, and patients were recruited from two centers in China. Progression‐free survival (PFS) and overall survival (OS) were compared, and the objective response rate (ORR) and disease control rate (DCR) were evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Treatment‐related adverse events (AEs) were analyzed to assess safety. Results The median follow‐up for the entire cohort was 11.4 months. Of the 103 patients included in this study, 56 received triple therapy, and 47 received doublet therapy. PFS was significantly higher in the triple therapy group than in the doublet therapy group (mPFS 22.5 vs. 14.0 months, P 
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.13773